Lockhart review backs therapeutic cloning
20 December, 2005 by Ruth BeranThe independent stem cell legislation review committee chaired by former Federal Court judge John Lockhart has given its support for somatic cell nuclear transfer (SCNT), sometimes known as therapeutic cloning.
Sydney team develops new blood test
12 December, 2005 by Ruth BeranScientists in Sydney have developed a new blood test to detect regulatory T cells, a subset of white cells that protect against the development of autoimmune and inflammatory diseases such as type I diabetes, multiple sclerosis, Crohn's disease and ulcerative colitis.
First patients recruited in Mesoblast stem cell trials
08 December, 2005 by Ruth BeranThe first few patients have been formally recruited for two pilot clinical trials of Melbourne-based Mesoblast's (ASX:MSB) adult stem cell platform technology.
Stem Cell Centre's DeVore to relocate back to US
07 December, 2005 by Ruth BeranAfter three years with the Australian Stem Cell Centre (ASCC), Dr Dianna DeVore has resigned as vice-president of clinical cardiac development, and will be returning to California to pursue stem cell collaborative opportunities, effective December 31.
Garvan team links molecule to stress
06 December, 2005 by Graeme O'NeillResearchers at Sydney's Garvan Medical Research Institute may have provided an explanation for the dramatic breakdown of champion Australian marathon runner Lisa Martin-Ondieki at the Barcelona Olympics in 1992.
The promise of stem cells
30 November, 2005 by Ruth BeranRuth Beran finds that few people want to stick their necks out when it comes to touting the benefits of stem cell research.
Stem cell photo exhibition to tour Australia
25 November, 2005 by Ruth BeranA photo exhibition featuring images of stem cells in their various forms was opened today in Melbourne by Senator Natasha Stott Despoja.
Stem Cell Centre CEO boycotts AusBiotech conference
18 November, 2005 by Ruth BeranAustralian Stem Cell Centre (ASCC) CEO Dr Hugh Niall is to boycott the AusBiotech conference, which begins in Perth next week, where he was due to appear on a panel with South Korean stem cell expert Prof Woo-Suk Hwang.
SCS Japanese affiliate signs cell therapy agreement
16 November, 2005 by Ruth BeranStem Cell Sciences KK (SCS KK), a Japanese affiliate of Stem Cell Sciences (AIM:STEM, SCS), has signed a worldwide exclusive license agreement with the University of Nice to commercialise tissue stem cells that may have therapeutic application in degenerative diseases such as Duchenne Muscular Dystrophy (DMD).
Norwood Immunology to seek IPO in US
15 November, 2005 by Ruth BeranImmune therapy developer and Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology (AIM:NIM) has revealed plans to seek an initial public offering (IPO) in the USA, subject to market conditions.
Canola taskforce finds small contamination
14 November, 2005 by Graeme O'NeillThe taskforce appointed by the Australian Oilseeds Federation and the Australian Seeds Federation to investigate the recent detection of genetically modified canola seed in a small, non-GM shipment has found the contamination was limited to just one commercial cultivar.
SCS licenses gene expression tech to Lexicon
04 November, 2005 by Ruth BeranStem Cell Sciences (AIM:STEM, SCS) has granted US-based biopharmaceutical company Lexicon Genetics an exclusive license to its Internal Ribosome Entry Site (IRES) technology for genetically modified mice.
Select Vaccines reports promising results for hep C
21 October, 2005 by Susan WilliamsonSelect Vaccines reports promising results for hep C
In brief: Australian Stem Cell Centre, Biotech Capital, Circadian, Alexanders Securities
19 October, 2005 by Ruth BeranProf Vicki Sara has been appointed as director of the Australian Stem Cell Centre and will replace inaugural chairman Robert Moses when he relinquishes the role he has held for three years at the Annual General Meeting (AGM) on November 22. Sara is the chancellor of the University of Technology, Sydney, a fellow of the Australian Academy of Technological Science and Engineering and a former head of the Australian Research Council.
Panbio develops new type of antibody assay
14 October, 2005 by Graeme O'NeillBrisbane medical diagnostics developed Panbio (ASX:PBO) believes it has achieved a milestone in its efforts to develop a new type of antibody assay capable of directly detecting target antigens at low concentrations in antigenically complex biological fluids.
